Nucleus Network has recently opened its expanded facility in Sydney for Phase I clinical trials. Credit: Nucleus Network. There is no denying that Australia hits above its weight class in early ...
Moderna’s CEO Stéphane Bancel virtually attended the Financial Times Global Pharma and Biotech Summit on 10 November. Moderna’s mRNA-based vaccine intismeran in combination w ...
Oyster Therapeutics has closed a $60m Series A-2 financing round to advance targeted protein degraders for neurodegenerative diseases including Alzheimer’s.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results